Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer

Showing 15 posts of 150 posts found.

boehringer_angle_22

Giotrif increases lung cancer survival

May 16, 2014
Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer

Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …

News
Boehringer image

Boehringer launches new transparency regime

May 12, 2014
Research and Development, Sales and Marketing Boehringer, LEO Pharma, all trials, csr, transparency

Boehringer is making good on its 2013 promise to release more clinical trial data to researchers with the launch of …

News
Merck image

Merck’s vorapaxar gains long-awaited FDA approval

May 9, 2014
Sales and Marketing Boehringer, FDA, Merck, lilly, vorapaxar, zontivity

Merck’s heart drug vorapaxar has finally been given the FDA go-ahead after looking dead in the water less than two …

News
Bayer image

Bayer to make $14 bn move for Merck unit

May 2, 2014
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Merck, Novartis, Reckitt Benckiser, claritin, reuters

Bayer is in talks with Merck & Co to buy its consumer business and is willing to pay $14 billion …

News

Boehringer: ‘devil in detail’ on new drug pricing policy

April 10, 2014
Medical Communications, Sales and Marketing Boehringer, PPRS, VBP, Zinta Krumins, alltrials, vba

Zinta Krumins, the newly-appointed managing director of Boehringer Ingelheim UK and Ireland, has warned that the ‘devil is in the …

News

CHMP recommends Jardiance

March 24, 2014
Research and Development, Sales and Marketing Boehringer, CHMP, EU, diabetes, jardiance, lilly

Boehringer Ingelheim and Eli Lilly’s type 2 diabetes treatment Jardiance is among nine medicines which the Committee for Medicinal Products …

News

Boehringer’s first cancer drug gains NICE yes

March 17, 2014
Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif

NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …

News
Sarah Edwards image

Breaking into the oncology market

March 10, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Cancer, NSCLC, edwards, gilotrif, oncology

In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …

Feature
Boehringer image

Manufacturing hitches cited for Lilly/BI drug rejection

March 6, 2014
Manufacturing and Production, Sales and Marketing Boehringer, FDA, diabetes, lilly, manufacturing

The FDA has refused to approve a new diabetes treatment from Lilly and its partner Boehringer Ingelheim due to ongoing …

News
pradaxa image

Boehringer in hot water over Pradaxa risks

February 19, 2014
Sales and Marketing Boehringer, Pradaxa, Xarelto, dabigatran, lawsuit

Boehringer Ingelheim attempted to delay and revise the publication of important drug information surrounding its new anticoagulant Pradaxa. This is …

News

Aveo and Astellas part ways

February 17, 2014
Sales and Marketing Astellas, Aveo, Boehringer, EMA, tivozanib

Aveo Oncology and Astellas Pharma are to abandon their three-year old collaboration and licence agreement for investigational tyrosine kinase inhibitor …

News

‘More than 2,000’ US lawsuits for Boehringer

February 14, 2014
Sales and Marketing Boehringer, Pradaxa, Xarelto, blood thinner, warfarin

Boehringer Ingelheim is facing more than 2,000 lawsuits in the US over allegations that its stroke prevention pill Pradaxa has …

News

Boehringer launches psychiatric research project

December 23, 2013
Research and Development, Sales and Marketing Boehringer, circuit, psychiatry

Boehringer Ingelheim has announced it will collaborate on a new three-year programme to investigate the neural foundations of psychiatric disorders.  …

News

EMA speeds up Boehringer review

November 28, 2013
Sales and Marketing Boehringer, faldaprevir, hepc

Boehringer Ingelheim’s hepatitis C candidate faldaprevir has moved a potential step closer to market with the news that the European …

News

New online tool to hear lung cancer patients’ stories

October 29, 2013
Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer

The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …

News

Latest content

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023